Trending Tickers : BP plc (NYSE:BP), Epiq Systems (NASDAQ:EPIQ), Synthesis Energy Systems (NASDAQ:SYMX), Advaxis, Inc. (NASDAQ:ADXS), Vale S.A. (NYSE:VALE)

Technology Stocks News 18

BP Plc (NYSE:BP) asked a U.S. court on Tuesday to fire the court-appointed lawyer tasked with paying out compensation to people affected by the 2010 Gulf of Mexico oil spill, saying Patrick Juneau had not disclosed an alleged conflict of interest before taking the job.BP plc (NYSE:BP) belongs to Basic Materials sector. Its net profit margin is 2.70% and weekly performance is -2.78%. On last trading day company shares ended up $47.20. BP plc (NYSE:BP) distance from 50-day simple moving average (SMA50) is -5.16%.

Epiq Systems, Inc. (NASDAQ:EPIQ), a leading global provider of managed technology for the legal profession, on 12 Aug 2014 announced the appointment of Douglas M. Gaston as an independent director effective August 11.  Mr. Gaston recently retired as Regional Managing Partner for BKD, LLP, a national accounting and advisory firm, where he had been a partner for close to 25 years. Epiq Systems, Inc. (NASDAQ:EPIQ) shares moved up 1.65% in last trading session and ended the day at $14.79. EPIQ Gross Margin is 49.20% and its return on assets is 1.20%. Epiq Systems, Inc. (NASDAQ:EPIQ) quarterly performance is 23.66%.

Synthesis Energy Systems, Inc. (NASDAQ:SYMX) Monday, 25 Aug 2014 announced that its Board of Directors is strengthening the company’s operational capabilities by putting more experienced and high level resources to accelerate and improve financial performance of its multiple global initiatives, including distributed power, DRI steel and Chinese joint ventures. On 02 September, Synthesis Energy Systems, Inc. (NASDAQ:SYMX) shares moved down -7.44% and was closed at $1.12. SYMX EPS growth in last 5 year was 16.20%. Synthesis Energy Systems, Inc. (NASDAQ:SYMX) year to date (YTD) performance is 86.67%.

Advaxis, Inc. (NASDAQ:ADXS), a clinical-stage biotechnology company developing cancer immunotherapies, has entered into a clinical trial collaboration agreement with Merck, known as MSD outside the United States and Canada, through its subsidiaries, to evaluate the combination of Advaxis’s Lm-LLO cancer immunotherapy, ADXS-PSA, with Merck’s investigational anti PD-1 antibody, pembrolizumab. Advaxis, Inc. (NASDAQ:ADXS) ended the last trading day at $4.27. Company weekly volatility is calculated as 8.41%and price to cash ratio as 2.98. Advaxis, Inc. (NASDAQ:ADXS) showed a weekly performance of 6.75%.

Mining giant VALE SA (NYSE:VALE) reported a 15% plunge in its second-quarter profit due to the fall in prices of iron ore, its main product. However, its peers Bhp Billiton (LONDON:BLT) and Rio Tinto (LONDON:RIO) reported an increase in earnings mostly attributable to their cost reduction efforts which helped mitigate the effect of lower iron prices. Vale S.A. (NYSE:VALE) shares moved down -1.76% in last trading session and ended the day on $12.83. VALE Gross Margin is 45.20% and its return on assets is 0.50%. Vale S.A. (NYSE:VALE) quarterly performance is 1.18%.

Signup for free to be the first to receive exclusive free links. Now in your mailbox!
Join over 15,000 subscribers
Send me links

Your information will not be shared to anyone